[1]谷青青,王志霞,高新愿,等.慢性阻塞性肺疾病患者血清Clara细胞分泌蛋白、转化生长因子-β1水平与肺功能的相关性[J].新乡医学院学报,2020,37(7):652-656.[doi:10.7683/xxyxyxb.2020.07.013]
　GU Qingqing,WANG Zhixia,GAO Xinyuan,et al.Correlation between serum clara cell secretory protein,transforming growth factor-β1 levels and pulmonary function in patients with chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2020,37(7):652-656.[doi:10.7683/xxyxyxb.2020.07.013]
点击复制

慢性阻塞性肺疾病患者血清Clara细胞分泌蛋白、转化生长因子-β1水平与肺功能的相关性
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年7
页码:
652-656
栏目:
临床研究
出版日期:
2020-07-05

文章信息/Info

Title:
Correlation between serum clara cell secretory protein,transforming growth factor-β1 levels and pulmonary function in patients with chronic obstructive pulmonary disease
作者:
谷青青; 王志霞; 高新愿; 高　静; 袁晓梅
（新乡医学院第一附属医院呼吸内科，河南　卫辉　453100）
Author(s):
GU Qingqing; WANG Zhixia; GAO Xinyuan; GAO Jing; YUAN Xiaomei
(Department of Respiratory Medicine,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
慢性阻塞性肺疾病; Clara细胞分泌蛋白; 转化生长因子-β1; 肺功能; 诊断价值
Keywords:
chronic obstructive pulmonary disease; clara cell secretory protein; transforming growth factor-β1; pulmonary function; diagnostic value
分类号:
R563
DOI:
10.7683/xxyxyxb.2020.07.013
文献标志码:
A
摘要:
目的　探讨慢性阻塞性肺疾病（COPD）患者血清Clara细胞分泌蛋白（CC16）、转化生长因子-β1（TGF-β1）水平与肺功能的相关性。方法　选择2018年5月至2019年7月新乡医学院第一附属医院呼吸内科收治的COPD患者100例为观察对象（COPD组），并按照气流受限程度的肺功能分级将COPD组患者分为轻中度组（n=39）、重度组（n=40）和极重度组（n=21）；另选择同期体检健康者50例为对照组。所有受试者于入组当天抽取空腹肘静脉血，检测血清CC16、TGF-β1水平，并采用肺功能检测仪检测肺功能。采用Spearman相关分析COPD患者血清CC16、TGF-β1与第1秒用力呼气容积占预计值百分比（FEV1%pred）、第1秒用力呼气容积与用力肺活量比值（FEV1/FVC）的相关性，采用受试者工作特征（ROC）曲线分析血清CC16、TGF-β1在COPD中的诊断价值。结果　COPD组患者的FEV1%pred、FEV1/FVC显著低于对照组（Z=-8.813、-9.967，P<0.05）。COPD组患者血清CC16水平低于对照组，血清TGF-β1水平高于对照组（Z=-7.288、-7.144，P<0.05）。COPD重度组和极重度组患者血清CC16水平低于COPD轻中度组（P<0.05），COPD极重度组患者血清CC16水平低于COPD重度组（P<0.05）；COPD重度组和极重度组患者血清TGF-β1水平高于COPD轻中度组（P<0.05），COPD极重度组患者血清TGF-β1水平高于COPD重度组（P<0.05）。COPD患者血清CC16水平与FEV1%pred、FEV1/FVC %呈正相关（r=0.819、0.684，P<0.01），血清TGF-β1水平与FEV1%pred、FEV1/FVC %呈负相关（r= -0.821、 -0.761，P<0.01）。CC16诊断COPD的ROC曲线下面积为0.866（P<0.05），临界值为98.13 μg·L-1，灵敏度为72.0%，特异度为98.0%，约登指数为0.72；TGF-β1诊断COPD的ROC曲线下面积为0.858（P<0.05），临界值为688.20 ng·L-1，灵敏度为74.0%，特异度为96.0%，约登指数为0.70。结论　血清CC16、TGF-β1水平与COPD患者肺功能有相关性，对COPD具有一定的诊断价值，可用于COPD患者气流受限程度的评估，有望成为辅助COPD临床诊断的新型生物标志物。
Abstract:
Objective　To investigate the correlation between serum clara cell secretory protein(CC16),transforming growth factor-β1(TGF-β1) levels and pulmonary function in patients with chronic obstructive pulmonary disease(COPD).Methods　One hundred patients with COPD admitted to Department of Respiratory,the First Affiliated Hospital of Xinxiang Medical University were selected as subjects.According to the lung function classification of the airflow limitation,the patients were divided into mild-moderate group (n=39),severe group (n=40) and extremely severe group (n=21);and 50 healthy persons in the same period were selected as control group.The fasting elbow venous blood of all subjects was extracted on the day of enrollment,and the serum CC16 and TGF-β1 levels were detected.The lung function was detected by lung function tester.The correlation between serum CC16,TGF-β1 and one second forced expiratory volume as a percentage of the expected value (FEV1%pred),ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) in patients with COPD was analyzed by Spearman correlation.Receiver operating characteristic(ROC) curve was used to analyze the diagnostic value of serum CC16 and TGF-β1 in COPD.Results　The FEV1%pred and FEV1/FVC in the COPD group were significantly lower than those in the control group (Z=-8.813,-9.967;P<0.05).The serum CC16 level in the COPD group was lower than that in the control group,and the serum TGF-β1 level was higher than that in the control group (Z=-7.288,-7.144;P<0.05).The serum CC16 level in the severe and extremely severe groups was lower than that in the mild-moderate group (P<0.05),and the serum CC16 level in the extremely severe group was lower than that in the severe group (P<0.05).The serum TGF-β1 level of COPD patients in the severe and extremely severe groups was higher than that in the mild-moderate group (P<0.05),and the serum TGF-β1 level of COPD patients in the extremely severe group was higher than that in the severe group(P<0.05). The serum CC16 level was positively correlated with FEV1%pred and FEV1/FVC% (r=0.819,0.684;P<0.01),and serum TGF-β1 level was negatively correlated with FEV1%pred and FEV1/FVC% in COPD patients (r=-0.821,-0.761;P<0.01).The area under the ROC curve of CC16 level for the diagnosis of COPD was 0.866 (P<0.05),the critical value was 98.13 μg·L-1,the sensitivity was 72.0%,the specificity was 98.0%,and the Youden index was 0.72;the area under the ROC curve of TGF-β1 level for the diagnosis of COPD was 0.858 (P<0.05),the critical value was 688.20 ng·L-1,the sensitivity was 74.0%,the specificity was 96.0%,and the Youden index was 0.70.Conclusion　The levels of serum CC16 and TGF-β1 are correlated with the lung function of COPD patients.They have certain diagnostic value in the diagnosis of COPD and can be used to evaluate the severity of airflow limitation in COPD patients.It is expected to become a new biomarker to assist clinical diagnosis of COPD.

参考文献/References:

［1］　陈梅鹃,王滔,王利.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗对慢性阻塞性肺疾病急性加重期疗效观察［J］.解放军医学院学报,2018,39(10):877-880.
［2］　VITENBERGA Z,PILMANE M,BABJONISEVA A.The evaluation of inflammatory,anti-inflammatory and regulatory factors contributing to the pathogenesis of COPD in airways ［J］.Pathol Res Pract,2019,215(1):97-105.
［3］　ZHAI J,INSEL M,ADDISON K J,et al.Club cell secretory protein deficiency leads to altered lung function ［J］.Am J Respir Crit Care Med,2019,199(3):302-312.
［4］　LACHAPELLE P,LI M,DOUGLASS J,et al.Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease ［J］.Pharmacol Ther,2018,187:98-113.
［5］　中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南：2013年修订版 ［J］.中国医学前沿杂志：电子版,2014,6(2):67-80.
［6］　李林静,李华旭,闫东星,等.N-乙酰半胱氨酸联合有氧运动对慢性阻塞性肺疾病稳定期患者肺功能、生活质量及血清氧化因子的影响［J］.新乡医学院学报,2018,35(5):407-410.
［7］　李勇,焉春华,邵玉霞.慢性阻塞性肺疾病气道重塑的研究进展 ［J］.临床肺科杂志,2018,23(9):181-183.
［8］　袁晓梅,李华旭,孙致远,等.N-乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期患者肺功能及血清炎性因子的影响［J］.新乡医学院学报,2018,35(4):306-309.
［9］　李锋,周新.慢性阻塞性肺疾病的发病机制研究进展 ［J］.中国呼吸与危重监护杂志,2019,18(1):88-92.
［10］　陈璐,黄超,冷冬月,等.补肾益肺方联合沙美特罗替卡松治疗慢性阻塞性肺疾病肺部感染患者的临床研究［J］.世界中医药,2019,14(12):3286-3289.
［11］　张涛,刘改霞,李耀辉,等.清肺化痰法治疗慢性阻塞性肺疾病急性加重期疗效的系统评价和Meta分析［J］.世界中医药,2019,14(5):1181-1187.
［12］　MANNINO D M.Biomarkers for chronic obstructive pulmonary disease diagnosis and progression:insights,disappointments and promise ［J］.Curr Opin Pulm Med,2019,25(2):144-149.
［13］　EAPEN M S,MYERS S,WALTERS E H,et al.Airway inflammation in chronic obstructive pulmonary disease (COPD):a true paradox［J］.Expert Rev Respir Med,2017,11(10):827-839.
［14］　张晓荣,戴红霞,魏红艳,等.呼吸窘迫综合征早产儿血清Clara细胞分泌蛋白水平变化及意义［J］.新乡医学院学报,2020,37(4):347-350.
［15］　马青,王导新.CC16在慢性阻塞性肺疾病中的研究进展 ［J］.中国免疫学杂志,2019,35(5):631-634.
［16］　BARNES P J.Inflammatory mechanisms in patients with chronic obstructive pulmonary disease［J］.J Allergy Clin Immunol,2016,138(1):16-27.
［17］　SAITO A,HORIE M,NAGASE T.TGF-β signaling in lung health and disease［J］.Int J Mol Sci,2018,19(8):2460.
［18］　CHIANG C H,CHUANG C H,LIU S L.Transforming growth factor-beta1 and tumor necrosis factor-alpha are associated with cli-nical severity and airflow limitation of COPD in an additive manner ［J］.Lung,2014,192(1):95-102.
［19］　张毅,李娟,张弢,等.芪蛭皱肺颗粒对慢性阻塞性肺疾病模型大鼠TGF-β1、PDG表达的调控作用［J］.解放军医学杂志,2019,44(1):7-12.
［20］　GUERRA S,HALONEN M,VASQUEZ M M,et al.Relation between circulating CC16 concentrations,lung function,and development of chronic obstructive pulmonary disease across the lifespan:a prospective study ［J］.Lancet Respir Med,2015,3(8):613-620.
［21］　李泽伦,许浦生,崔志新，等.慢性阻塞性肺疾病患者血清IL-10、TGF-β1与FEV1%、FEV1/FVC及CAT评分的相关性分析 ［J］.临床肺科杂志,2017,22(09):1577-1580.
［22］　ZEMANS R L,JACOBSON S,KEENE J,et al.Multiple biomar-kers predict disease severity,progression and mortality in COPD ［J］.Respir Res,2017,18(1):117.
［23］　郑烯,胡雪峰.慢性阻塞性肺疾病发病机制的研究进展 ［J］.中国细胞生物学学报,2019,41(02):304-311.
［24］　孙印,何士杰.慢性阻塞性肺疾病患者血清中CCL18、CC16、IL-8的表达及临床意义 ［J］.医学理论与实践,2017,30(22):3302-3304.
［25］　SIN D D,LEUNG R,GAN W Q,et al.Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD:a pilot study ［J］.BMC Pulm Med,2007,7(1):13.
［26］　樊晓曦.老年慢性阻塞性肺疾病患者的血清激活素A和转化生长因子β1与肺功能变化的相关性 ［J］.临床和实验医学杂志,2016,15(10):975-977.
［27］　王烨林,丁以艳,孙思庆.穴位贴敷联合常规西药治疗慢性阻塞性肺疾病稳定期患者［J］.世界中医药,2020,15(3):463-467.
［28］　BHATT S P,BALTE P P,SCHWARTZ J E,et al.Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality［J］.JAMA,2019,321(24):2438-2447.
［29］　LAUCHO-CONTRERAS M E,POLVERINO F,TESFAIGZI Y,et al.Club cell protein 16 (CC16) augmentation:a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD) ［J］.Expert Opin Ther Targets,2016,20(7):869-883.
［30］　PILETTE C,GODDING V,KISS R,et al.Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease ［J］.Am J Respir Crit Care Med,2001,163(1):185-194.
［31］　GOHY S,CARLIER F M,FREGIMILICKA C,et al.Altered generation of ciliated cells in chronic obstructive pulmonary disease ［J］.Sci Rep,2019,9(1):17963.

相似文献/References:

[1]史册.慢性阻塞性肺疾病急性发作期的营养支持治疗[J].新乡医学院学报,2001,18(06):444.
[2]袁晓梅,孙 云,袁宇.慢性阻塞性肺疾病肺心病患者血浆内皮素测定的临床价值[J].新乡医学院学报,2002,19(04):273.
[3]郭志强.慢性阻塞性肺疾病60例院内获得性真菌感染与耐药性分析 [J].新乡医学院学报,2006,23(02):000.
[4]程思远.慢性阻塞性肺疾病继发真菌感染65例病原菌分布及耐药性分析[J].新乡医学院学报,2009,26(01):073.
[5]杨华,周志才,奚峰,等.无创正压通气治疗慢性阻塞性肺疾病急性加重期伴Ⅱ型呼吸衰竭[J].新乡医学院学报,2011,28(02):216.
[6]殷波,惠复新,赵寅滢,等.慢性阻塞性肺疾病急性加重期三重酸碱失衡与急性生理学和慢性健康状况评分Ⅲ评分及预后的关系 [J].新乡医学院学报,2011,28(03):346.
[7]刘金花,徐吟亚,付波.低分子肝素钙对慢性阻塞性肺疾病急性加重期患者血栓前状态的影响[J].新乡医学院学报,2012,29(09):680.
[8]王 沁,郭建辉,梁 栋,等.健脾益肺口服液对慢性阻塞性肺疾病“肺脾气虚证”大鼠动脉血气的影响[J].新乡医学院学报,2014,31(11):896.[doi:10.7683/xxyxyxb.2014.11.00]
[9]朱木林１,袁云华１,邓　巍２,等.慢性阻塞性肺疾病合并外周骨骼肌功能障碍患者炎性因子和代谢水平及线粒体功能的变化[J].新乡医学院学报,2015,32(05):412.
[10]李　航,郭伟丽,安　珍,等.PM2.5对慢性阻塞性肺疾病影响研究进展[J].新乡医学院学报,2016,33(3):234.[doi:10.7683/xxyxyxb.2016.03.020]
　LI Hang,GUO Weili,AN Zhen,et al.Research progress on the effect of PM2.5 on chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2016,33(7):234.[doi:10.7683/xxyxyxb.2016.03.020]

更新日期/Last Update: 2020-07-05